UPDATE 3-Biogen profit rises as new multiple sclerosis drug shines

Jan 29 (Reuters) - Biogen Idec Inc said on Wednesday its new, high-profile oral multiple sclerosis drug Tecfidera had sales of $398 million in the fourth quarter, easily exceeding estimates for a...

from Reuters: Mergers News http://ift.tt/1fcsRXH